Faruqi and Faruqui, LLP Logo
Share this page

Galectin Therapeutics, Inc. (GALT)

(NasdaqCM: GALT)

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Galectin Therapeutics, Inc. (GALT) To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Galectin Therapeutics, Inc. (“Galectin” or the “Company”) (NasdaqCM: GALT) of the September 29, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Galectin and certain executives.

A complaint has been filed in the United District Court of Nevada on behalf of all persons who purchased Galectin securities between January 6, 2014 and July 28, 2014, inclusive (the “Class Period”).

The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.

Specifically, the action alleges that during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Galectin paid stock promoters to distribute positive but false reports about the Company’s prospects; (2) GR-MD-02 failed to provide the benefits proposed by Defendants when discussing the patent; and (3) as a result of the above, the Company's financial statements were materially false and misleading at all relevant times.

On July 28, 2014, Bleecker Street Research published an article disclosing that Galectin has connections with multiple stock promoters, insiders sold stock in the midst of a campaign to promote.

Also on July 28, 2014, Adam Feuerstein published an article reporting that Galectin paid Emerging Growth Corp.  to disseminate misleading promotional campaigns about its stock.

Following this news, the price of Galectin stock declined by $0.78, or over 5%, to close at $14.54 on July 28, 2014.

On July 29, 2014, Galectin published the results of GR-MD-02 phase 1 clinical trial on its website, suggesting that it showed little difference from a placebo.

On July 29, Adam Feuerstein published an article stating that the Company deemed the phase 1 trial to be a success because there were no adverse side effects, despite knowing that ineffective placebos do not raise safety concerns.

On this news, the price of Galectin stock declined by $8.84, or over 61%, to close at $5.70 on July 29, 2014.

Take Action

If you invested in Galectin stock or options between January 6, 2014 and July 28, 2014 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Galectin’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 08/22/2014

Class Period:

  • 01/06/2014 - 07/28/2014

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.